Connor Clark & Lunn Investment Management Ltd. Invests $4.37 Million in Dynavax Technologies Corporation (NASDAQ:DVAX)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 336,951 shares of the biopharmaceutical company's stock, valued at approximately $4,370,000. Connor Clark & Lunn Investment Management Ltd. owned 0.28% of Dynavax Technologies at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. DekaBank Deutsche Girozentrale acquired a new position in shares of Dynavax Technologies in the first quarter valued at $30,000. Russell Investments Group Ltd. raised its stake in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies in the fourth quarter valued at $35,000. GAMMA Investing LLC raised its stake in shares of Dynavax Technologies by 88.4% in the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Dynavax Technologies in the first quarter valued at $131,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $10.82 on Thursday. The business's fifty day moving average price is $10.54 and its two-hundred day moving average price is $11.52. Dynavax Technologies Corporation has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -23.52 and a beta of 1.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The firm had revenue of $95.44 million for the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. As a group, analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. JMP Securities upped their price target on Dynavax Technologies from $31.00 to $32.00 and gave the company a "market outperform" rating in a research report on Friday, August 8th. Finally, The Goldman Sachs Group lowered their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.